January 31, 2015     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Client Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 
Suprema Provides Palm-print Live Scanners to Poland & Lithuania
Suprema Provides Palm-print Live Scanners to Poland & Lithuania
Seoul, Nov 23, 2010 - (ACN Newswire) - Suprema, Inc., a global leader in biometrics and ID solutions, announced today that the company's RealScan-F palm-print live scanner has been selected for the AFIS systems of the Polish National Police and Lithuania's Citizenship & Migration Affairs.   [ more... ]

 Headline News

Otsuka Announces Termination of Contracts (Jan 8, 2015)
Otsuka Pharmaceutical Co., Ltd. announces the termination of exclusive licensing contract with OncoTherapy Science and sublicensing contract with Fuso Pharmaceutical Industries. more info >>
Otsuka: U.S. FDA Approves Labeling Update of Abilify Maintena (Aripiprazole) (Dec 8, 2014)
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced that the U.S. Food and Drug Administration (FDA) approved the labeling update of Abilify Maintena (aripiprazole) for extended-release injectable suspension. more info >>
Otsuka Pharmaceutical to Launch L-Cartin FF Tablets for Carnitine Deficiencies in Japan (Dec 1, 2014)
On December 5, Otsuka Pharmaceutical is launching a new form of L-Cartin, L-Cartin Free Form (FF) tablets (generic name levocarnatine) in two doses, 100mg and 250mg. more info >>
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka Pharmaceutical Co., Ltd. and Otsuka Foods Co., Ltd. have announced the establishment of Otsuka Wellness Vending Co., Ltd., a new corporate subsidiary that will focus on vending machine business. more info >>
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Otsuka Pharmaceutical's QuickNavi(TM)-Flu, a rapid diagnostic test kit for the influenza virus, has the leading market share in Japan among products in this category. more info >>
ACN Newswire
 Press Release News

Eisai's Phase II Trial of Anticancer Agent Lenvatinib in Renal Cell Carcinoma Meets Primary Endpoint (Jan 30, 2015)
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the Phase II part of a Phase I/II clinical trial (Study 205) of its in-house developed anticancer agent lenvatinib mesylate (lenvatinib) in unresectable advanced or metastatic renal cell carcinoma has met its primary endpoint. more info >>
NEC Delivers Infrared Thermography Cameras as a Countermeasure Against Ebola (Jan 27, 2015)
NEC Corporation today announced the delivery of infrared thermography cameras(1), via the Japan International Cooperation Agency (JICA), to support countermeasures against Ebola hemorrhagic fever in Africa, delivering 4 units to the Republic of Cote d'Ivoire, and 5 units to the Republic of Ghana. more info >>
Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in The Philippines (Jan 26, 2015)
Eisai Co., Ltd. and Ajinomoto Pharmaceuticals Co., Ltd. announced today that LIVAMIN Oral Granules (granules of isoleucine, leucine and valine, brand name in Japan: LIVACT Granules), a branched-chain amino acid formula, was launched in the Philippines. more info >>
Eisai Listed In Global 100 Sustainability Index for Third Consecutive Year (Jan 23, 2015)
Eisai Co., Ltd. announced today that it has been listed in the 2015 Global 100 Most Sustainable Corporations in the World (Global 100) Index, a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >>
Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures Conducted in Asia Including Japan and China Meets Primary Endpoint (Jan 5, 2015)
Eisai Co., Ltd. announced today that a Phase III clinical trial (Study 335) of its in-house-discovered antiepileptic drug (AED) perampanel in patients with refractory partial-onset seizures conducted in Asia (including Japan and China) has met its primary endpoint. more info >>
 Global Press Release

Eisai's Phase II Trial of Anticancer Agent Lenvatinib in Renal Cell Carcinoma Meets Primary Endpoint (Jan 30, 2015)

NEC Delivers Infrared Thermography Cameras as a Countermeasure Against Ebola (Jan 27, 2015)

Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in The Philippines (Jan 26, 2015)

Eisai Listed In Global 100 Sustainability Index for Third Consecutive Year (Jan 23, 2015)

Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures Conducted in Asia Including Japan and China Meets Primary Endpoint (Jan 5, 2015)

JCN Network - Company Profiles - Company Listing
 
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)